In Brief: Medtronic/Regeneron
This article was originally published in The Gray Sheet
Medtronic/Regeneron: Firms enter agreement to co-develop "a family of therapeutics for central nervous system diseases and disorders" using experimental Regeneron compounds and Medtronic delivery systems. The initial project under the agreement will be development of Regeneron's Axokine, delivered using a Medtronic implantable pump, for treatment of Huntington's disease. Under terms of the deal, Medtronic has purchased 460,500 shares of Regeneron common stock for $10 mil. and has acquired five-year warrants to buy another 107,400 shares for $21.72 per share. Regeneron will conduct preclinical development of Axokine and "retains all rights to manufacture and commercialize" the drug. Medtronic, which will make milestone payments to Regeneron during the drug's development, retains rights to manufacture and sell the delivery devices, and will receive royalties on sales of drugs developed under the pact...
You may also be interested in...
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.